acute coronary syndrome without ST-segment elevation
Conditions
Interventions
FraxiParine group:Receive FraxiParine at a dose of 0.01 ml per kilogram of body weight twice daily by subcutaneous injection for two to eight days
fondaparinux group:Receive fondaparinux at a dose of 2.5 mg once daily by subcutaneous injection until hospital discharge or for up to eight days.
Sponsors
Beijing Anzhen Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Male and female aged 18 to 75 years old; 2. Patients with unstable angina or myocardial infarction without ST-segment elevation admitted within 24 hours after the onset of symptoms were eligible if they met at least one of the two following criteria: an elevated level of troponin or creatine kinase MB isoenzyme or electrocardiographic changes indicative of ischemia.
Exclusion criteria
Exclusion criteria: 1. Body weight less than 55 kg; 2. Having received low-molecular-weight heparin within 2 weeks before randomization; 3. Recent hemorrhagic stroke; 4. Indications for anticoagulation other than an acute coronary syndrome; 5. a serum creatinine level of at least 2 mg per deciliter (177 umol per liter) were excluded; 6. Refuse to participate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of major bleeding at nine days;Incidence of death, myocardial infarction, or refr; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of major bleeding at 1, 3 and 6 months;Incidence of death, myocardial infarction, or refractory ischemia at 1, 3 and 6 months; | — |
Countries
China
Contacts
Public ContactHongbing Yan
Outcome results
None listed